Tempus AI

Tempus AI Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Tempus AI (TEM) as of Nov 3, 2026 is 65.99. In the previous year, Cash Conversion Cycle (CCC) was 63.48 — a change of 3.96% (higher).

Cash Conversion Cycle

65.99

YoY

3.96%

Last updated:

Cash Conversion Cycle (CCC) of Tempus AI is 2025 65.99 . Cash Conversion Cycle (CCC) of Tempus AI was 2024 63.48 . It decreases by 3.96% higher compared to the previous year.

The Tempus AI Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
146.82 USD
Jan 1, 2020
132.71 USD
Jan 1, 2021
93.70 USD
Jan 1, 2022
55.52 USD
Jan 1, 2023
26.83 USD
Jan 1, 2024
63.48 USD
Jan 1, 2025
65.99 USD
The Tempus AI Cash Conversion Cycle history
YEARCash Conversion CycleYoY
65.99+3.96%
63.48+136.60%
26.83-51.68%
55.52-40.74%
93.70-29.40%
132.71-9.60%
146.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Cash Conversion Cycle (CCC) of Tempus AI is 65.99 in 2025.

Cash Conversion Cycle (CCC) of Tempus AI changed from 63.48 to 65.99, representing a 3.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Tempus AI since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tempus AI

All Key Metrics — Tempus AI